Back to top

What we do

We discover, develop, manufacture and market small molecules and biologics focused on three key areas – oncology; cardiovascular and metabolic diseases; and respiratory, inflammation and autoimmunity.

Pushing the boundaries of science

We are one of very few innovation-driven biopharmaceutical companies to span discovery, development, manufacturing, distribution and worldwide commercialisation. Even so, we’re constantly moving forward as a company – building a new kind of organisation, one that can improve the lives of 200 million patients and be a $50 billion company in 2025.

Our therapeutic areas

Cardiovascular and Metabolic disease (CVMD)

Cardiovascular and Metabolic disease (CVMD)

Our strategy is to focus on ways to reduce morbidity, mortality and organ damage by addressing multiple risk factors across cardiovascular (CV) disease, diabetes and chronic kidney-disease indications. This patient-centric approach is reinforced by science-led life-cycle management programmes and technologies, including early research into regenerative methods.

Oncology

Oncology

We want to redefine the cancer-treatment paradigm, and we aim to bring six new cancer medicines to patients by 2020. Our broad pipeline of next-generation medicines is focused principally on four disease areas – breast, ovarian, lung and haematological cancers. As well as other tumour types, these are being targeted through four key platforms: immunotherapy; the genetic drivers of cancer and resistance; DNA damage repair; and antibody drug conjugates. These are all underpinned by personalised healthcare and biomarker technologies.

Respiratory, Inflammation and Autoimmunity (RIA)

Respiratory, Inflammation and Autoimmunity (RIA)

AstraZeneca holds a unique position in respiratory disease, including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). We have a range of differentiated potential medicines in development by leveraging novel combinations, biologics and devices. Our pipeline also contains a number of promising assets in inflammatory and autoimmune diseases within areas such as psoriasis, psoriatic arthritis, gout, systemic lupus and rheumatoid arthritis.

Infection, Neuroscience and Gastrointestina

Infection, Neuroscience and Gastrointestina

AstraZeneca continues to push the boundaries of neuroscience in collaboration with other innovative partners across industry and academia. A significant unmet medical need remains in the areas of cognitive disorders, chronic pain and other central nervous system disorders. We also work to protect patients against the burden of influenza and bacterial infections, particularly those resistant to current antibiotics.

In Europe, antimicrobial resistance results in 25,000 deaths from hospital-acquired infections, while there are 3-5 million severe cases of influenza each year worldwide. AstraZeneca aims to translate science into solutions to address global challenges faced in these disease areas.

MedImmune

MedImmune is AstraZeneca’s worldwide biologics research and development arm. We work as partners on the discovery, development and commercialisation of small molecule and biologic prescription medicines. By prioritizing across the whole organization to increase speed, quality, and cost we’re able to focus on projects that we believe have the best chance of success. We explore novel biologics pathways and pioneer innovative research in protein engineering, translational sciences and immunology.
Find out more

Explore AstraZeneca and MedImmune

Innovative Medicines and Early Development

Innovative Medicines and Early Development

Our Innovative Medicines and Early Development (IMED) Unit drives forward research on small molecules, oligonucleotides and other emerging technologies and drug discovery platforms in our core therapy areas of oncology, respiratory and inflammation, and cardiovascular and metabolic disease. Our scientists and scientific management experts work from target identification to the end of Phase 2 trials. At IMED, collaboration is a way of life. We combine the great science developed in our labs with the very best external science, forming some of the most innovative partnerships in the industry. Each year we invest more than $1bn in the discovery and development of the next generation of life-changing medicines.

Global Medicines Development

Global Medicines Development

In Global Medicines Development (GMD), we turn exciting science and innovative molecules into medicines that change lives. And by driving the late stage development of our pipeline, we enable the business to make critical pipeline and investment decisions. We do this by working closely with our two biotech units – Innovative Medicines and Early Development (IMED) and MedImmune – as well as the Global Portfolio and Product Strategy (GPPS) organisation. A huge range of professionals help us, from manufacturing and quality specialists, to experts in regulatory and medical affairs. 

Global Product and Portfolio Strategy

Global Product and Portfolio Strategy

Global Product and Portfolio Strategy (GPPS) shapes AstraZeneca’s product and portfolio strategy. We integrate corporate, product and therapy area strategies to provide clear strategic direction that bridges our science and commercial teams. Our team includes business planners, marketing experts, business intelligence specialists and others. For strategic planners with sound business acumen, GPPS is a genuine springboard for future leadership.

Enabling

Enabling

Our business functions teams are behind the successful execution of our three business priorities: achieving scientific leadership; returning to growth; and making AstraZeneca a great place to work. From the legal experts who manage our intellectual property and contracts to the HR teams who seek out and attract the world’s best minds to the business, our Enabling teams do just that – they enable us to create life-changing medicines. And in an operation as large and complex as ours, there is plenty of scope for great careers. Our Finance teams work with $multi-billion turnovers, our Compliance experts help us work with dozens of different regulatory regimes, our Facilities teams manage complex sites across the globe and our Admin teams provide the vital support that our people need to give their very best.

Operations and IT

Operations and IT

If R&D is the lifeblood of AstraZeneca, Operations and IT are the muscle and the nerves. Our Operations teams provide the vital link between drug discovery & development and sales & marketing. Over 11,000 Manufacturing experts, Engineers and Supply chain professionals across more than 18 sites in 16 countries, work together to form one of the largest areas of our business. At the same time IT offers support and solutions across the global business. Solving complex problems and challenges, our IT teams enable innovation and increased growth by connecting technology and information systems with cutting edge science. Together, Operations and IT offer a panorama of vibrant, challenging careers.

Commercial

Commercial

Our commercial operation includes our global sales and marketing functions. We have sales operations in countries around the world, representing and promoting some of the most well recognised and respected products in the industry. Our sales teams enjoy exceptional industry training, as well as the opportunities provided by our robust pipeline. Our marketing professionals enjoy the challenge and variety that comes with managing communications and building relationships with everyone from medical practitioners and internal sales teams, to the media and the general public. One thing that all our commercial teams share is a passion for improving patient health – they feel inspired by our mission and the work we do. 

MedImmune

MedImmune

MedImmune is AstraZeneca’s worldwide biologics research and development arm. Wherever we can, we remove barriers between people, recreating the thrill and excitement of a cutting edge biotech start-up, but with the backing of a global biopharmaceutical leader. We work as partners, sharing and benefiting from each other's strengths in the pre-clinical, clinical, and commercial areas. Because of this, we can prioritise across the whole organisation to increase speed, quality, and cost – allowing us to focus on projects that we believe have the best chance of success.

Our pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
Find out more
Back to top